Clinical trialsCompany release

CervoMed presents interim 24-week NfL data for neflamapimod in nfvPPA at CTAD

🇺🇸 CervoMed Inc. (CRVO) · Mon 16 Nov 2026

Plasma neurofilament light chain stayed stable overall and fell at the highest drug exposures in the 19-patient US cohort of a Phase 2a trial, with no new safety signals.

CervoMed presented interim 24-week biomarker results on 16 November 2026 at the CTAD conference from its Phase 2a trial of oral neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CervoMed Inc. ↗

Article written by VigiEye from the official source (CervoMed Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →